Gå til indhold

Health & Life Sciences

Italy ranks among the leading pharmaceutical centres in the world, offering a compelling investment opportunity for the Danish Life science sector. With a population of about 59 million, Italy has a significant market potential for healthcare products, services and solutions. The country's healthcare system is considered one of the best in the world, with a universal healthcare system that ensures access to quality healthcare for all citizens.

The Italian Life science sector is one of the most productive of the Italian economy. Italy is the second largest producer of pharmaceuticals in Europe and the tenth in the world, with the industry accounting for a significant proportion of the country's exports. Approximately two-thirds of the Italian Life science industry is focused on pharmaceuticals, while the remaining third is made up of medical devices and biotech.

Italy is facing a significant challenge due to its ageing population and the prevalence of multiple chronic conditions, which will require more resources and funding in the coming years. This demographic shift offers opportunities for investment in health technologies, solutions and services that meet the needs of the population.

For these reasons, policies will be implemented to assure sustainability of the healthcare system and to attract investments. Through the National Recovery and Resilience Plan (NRRP) and the related national complementary funds, 20.2 Billion have been allocated to modernize the Italian healthcare system and the supply of technological and digital solutions to improve access and proximity of care.

If you are interested in knowing all the opportunities in Italy for your company, you can reach out to our team that has more than 25 years of experience working in the healthcare sector and who works to assist Danish Life science companies in the Italian market and support Public Affairs strategies to drive growth and innovation.